

## EMPLICURE'S BOARD MEMBER JOHAN WIESLANDER ACQUIRES ADDITIONAL WARRANTS OF SERIES TO1 AND EXERCISES THE WARRANTS FOR SUBSCRIPTION OF SHARES FOR APPROXIMATELY SEK 3.1 MILLION

Johan Wieslander, who is a board member of Emplicure AB (publ) ("Emplicure" or the "Company"), has acquired an additional 1,500,000 warrants of series TO1, in addition to the warrants previously held by him that have already been exercised for subscription of shares in the Company. Johan Wieslander has exercised the the additional 1,500,000 warrants for subscription of 1,500,000 shares in the Company, meaning that the Company receives approximately SEK 3.1 million.

### Summarized terms for warrants of series TO1:

Last day of exercise of TO1 for subscription of shares: May 13, 2022.

Subscription price: SEK 2.09 per share.

Volume: 9,600,000 warrants of series TO1. If all warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.

Last day for trading with warrants of series TO1: May 11, 2022.

### Advisors

Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.

For more information, please contact:

#### Torbjörn W. Larsson

CEO, Emplicure

Telephone: +46 707 476 599

E-mail: [torbjorn.walkerlarsson@emplicure.com](mailto:torbjorn.walkerlarsson@emplicure.com)

#### Erik Magnusson

CFO & Investor Relations, Emplicure

Telephone: +46 708 565 245

E-mail: [erik.magnusson@emplicure.com](mailto:erik.magnusson@emplicure.com)



*Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with dry white oral nicotine as the first product. Read more at [www.emplicure.com](http://www.emplicure.com)*